The Vitiligo Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Vitiligo Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vitiligo Market.
Get a Free Sample PDF Report to know more about Vitiligo Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/vitiligo-pipeline-insight
Some of the key takeaways from the Vitiligo Pipeline Report:
Companies across the globe are diligently working toward developing novel Vitiligo treatment therapies with a considerable amount of success over the years.
Vitiligo companies working in the treatment market are Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, and others, are developing therapies for the Vitiligo treatment
Emerging Vitiligo therapies in the different phases of clinical trials are- Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and others are expected to have a significant impact on the Vitiligo market in the coming years.
In May 2026, EDSA Biotech announced plans to initiate a Phase II clinical trial of its investigational vitiligo therapy in mid-2026, further advancing the clinical development pipeline for the disease.
In February 2026, NHS England approved reimbursement-backed access to ruxolitinib (Opzelura) cream for eligible patients aged 12 years and older with non-segmental vitiligo, broadening the availability of this treatment option across the United Kingdom.
In January 2026, The Vitiligo Research Foundation highlighted ongoing advancements in the vitiligo pipeline, including Bristol Myers Squibb’s deucravacitinib (Sotyktu), which is being evaluated in a Phase II/III trial in combination with NB-UVB phototherapy, and CAGE Bio’s CGB-600, which has advanced into Phase II clinical development for the treatment of facial non-segmental vitiligo.
Incyte’s Opzelura (ruxolitinib) cream continues to be the only U.S. FDA-approved treatment specifically indicated for non-segmental vitiligo in patients 12 years of age and older, following its landmark approval in July 2022. Since that approval, no new FDA-approved therapies for vitiligo have been introduced.
In March 2025, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology firm focused on developing, commercializing, and marketing innovative dermatologic treatment products, announced the findings of a newly published study in Japan. The study further confirms the technological benefits of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology compared to other UVB light sources, which are less precise and lack the repetition rate and fluence capabilities of Excimer Light for treating conditions such as Vitiligo, Psoriasis, Alopecia Areata, and Atopic Dermatitis.
In February 2025, Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company specializing in host-directed therapies for immuno-inflammatory diseases, today announced its financial results for the quarter ending December 31, 2024, along with a business update. During this period, the company made progress with its lead asset, EB06, an anti-CXCL10 monoclonal antibody candidate aimed at providing effective and lasting treatment for vitiligo.
In January 2025, VYNE Therapeutics, a US-based pharmaceutical company, completed patient enrollment in its randomized Phase IIb clinical trial evaluating VYN201 gel (repibresib) for the treatment of non-segmental vitiligo. This double-blind, vehicle-controlled study is examining the safety, pharmacokinetics, and effectiveness of a once-daily application of the gel across three dosage groups—1%, 2%, and 3%—in comparison to a vehicle.
Vitiligo Overview
Vitiligo is a chronic skin condition where the skin loses its pigment (color) due to the destruction or malfunction of melanocytes the cells responsible for producing melanin (skin pigment).
This leads to the development of white patches on various parts of the body, including the skin, hair, and sometimes even inside the mouth or eyes.
Explore the latest Vitiligo pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Vitiligo Clinical Trials
Emerging Vitiligo Drugs Under Different Phases of Clinical Development Include:
Phimelanotide: Clinuvel Pharmaceuticals
BNZ-1: Bioniz Therapeutics
TAGX-0003: TAGCyx Biotechnologies
TT-01: Temprian Therapeutics
ATI-1777: Aclaris Therapeutics
AC-1101: TWi Biotechnology
Cerdulatinib: Dermavant Science
AMG 714: Amgen
Ritlecitinib: Pfizer
Ruxolitinib: Incyte Corporation
Afamelanotide: Clinuvel Pharmaceuticals Limited
Crisaborole 2% Topical Ointment: Pfizer
Vitiligo Route of Administration
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type
Vitiligo Molecule Type
Vitiligo Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Vitiligo Pipeline Therapeutics Assessment
Vitiligo Assessment by Product Type
Vitiligo By Stage and Product Type
Vitiligo Assessment by Route of Administration
Vitiligo By Stage and Route of Administration
Vitiligo Assessment by Molecule Type
Vitiligo by Stage and Molecule Type
DelveInsight’s Vitiligo Report covers around 25+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Vitiligo product details are provided in the report. Download the Vitiligo pipeline report to learn more about the emerging Vitiligo therapies
Some of the key companies in the Vitiligo Therapeutics Market include:
Key companies developing therapies for Vitiligo are – Dermavant Sciences, Incyte Corporation, TWi Biotechnology, Aclaris Therapeutics, Dermira, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, Bioniz Therapeutics, among others.
Vitiligo Pipeline Analysis:
The Vitiligo pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
Vitiligo key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Vitiligo drugs and therapies
Vitiligo Pipeline Market Drivers
Increasing awareness, demand of novel therapies, large patient pool and better healthcare infrastructure are some of the important factors that are fueling the Vitiligo Market.
Vitiligo Pipeline Market Barriers
However, patient compliance, chronic nature of disease and long term therapy, lack of adequate financial assistance & stringent regulatory procedure and other factors are creating obstacles in the Vitiligo Market growth.
Scope of Vitiligo Pipeline Drug Insight
Coverage: Global
Key Vitiligo Companies: Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, and others
Key Vitiligo Therapies: Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and others
Vitiligo Therapeutic Assessment: Vitiligo current marketed and Vitiligo emerging therapies
Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers
Request for Sample PDF Report for Vitiligo Pipeline Assessment and clinical trials
Table of Contents
1. Vitiligo Report Introduction
2. Vitiligo Executive Summary
3. Vitiligo Overview
4. Vitiligo- Analytical Perspective In-depth Commercial Assessment
5. Vitiligo Pipeline Therapeutics
6. Vitiligo Late Stage Products (Phase II/III)
7. Vitiligo Mid Stage Products (Phase II)
8. Vitiligo Early Stage Products (Phase I)
9. Vitiligo Preclinical Stage Products
10. Vitiligo Therapeutics Assessment
11. Vitiligo Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Vitiligo Key Companies
14. Vitiligo Key Products
15. Vitiligo Unmet Needs
16 . Vitiligo Market Drivers and Barriers
17. Vitiligo Future Perspectives and Conclusion
18. Vitiligo Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
